Back to top
more

Harpoon Therapeutics, Inc. (HARP)

(Delayed Data from NSDQ)

$15.34 USD

15.34
48,004

+0.32 (2.13%)

Updated Oct 23, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.53%
2Buy17.99%
3Hold9.63%
4Sell5.14%
5Strong Sell2.00%
S&P50010.72%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (171 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for HARP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Harpoon Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents 148 89 29 0 NA
Receivables 0 0 0 0 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 0 0 0 NA
Other Current Assets 3 1 0 0 NA
Total Current Assets 151 90 30 0 NA
Net Property & Equipment 11 3 2 0 NA
Investments & Advances 7 0 0 0 NA
Other Non-Current Assets 0 6 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 0 0 0 0 NA
Deposits & Other Assets 1 4 0 0 NA
Total Assets 177 103 32 0 NA
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable 0 0 0 0 NA
Accounts Payable 3 4 1 0 NA
Current Portion Long-Term Debt 0 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 8 3 1 0 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 11 4 4 0 NA
Total Current Liabilities 23 12 7 0 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 46 8 12 0 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 0 0 0 0 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 0 7 0 0 NA
Minority Interest (Liabilities) 0 130 40 0 NA
Total Liabilities 82 156 59 0 NA
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock 0 0 0 0 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 212 9 8 0 NA
Retained Earnings -118 -63 -35 0 NA
Other Equity 0 0 0 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 94 -53 -27 0 NA
Total Liabilities & Shareholder's Equity 177 103 32 0 NA
Total Common Equity 94 -53 -27 0 0
Shares Outstanding 24.60 NA NA NA NA
Book Value Per Share 3.83 0.00 0.00 0.00 0.00

Fiscal Year End for Harpoon Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Assets          
Cash & Equivalents NA 172 123 148 121
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 3 6 3 2
Total Current Assets NA 175 129 151 123
Net Property & Equipment NA 11 11 11 12
Investments & Advances NA 4 15 7 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 1 1 1 1
Total Assets NA 197 163 177 142
Liabilities & Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 2 2 3 4
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 9 7 8 8
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 27 14 11 4
Total Current Liabilities NA 39 24 23 17
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 73 42 46 4
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 125 79 82 35
Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 215 214 212 211
Retained Earnings NA -143 -131 -118 -104
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 72 83 94 107
Total Liabilities & Shareholder's Equity NA 197 163 177 142
Total Common Equity 0 72 83 94 107
Shares Outstanding 25.10 25.00 25.00 24.60 24.50
Book Value Per Share 0.00 2.88 3.33 3.83 4.38